Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Cabometyx
(United States) [Available] ,Cometriq
(United States) [Available]Synonyms :
Cabozantinib
Class :
Antineoplastics and Tyrosine Kinase Inhibitor
Brand Name :
Cabometyx
(United States) [Available] ,Cometriq
(United States) [Available]Synonyms :
Cabozantinib
Class :
Antineoplastics and Tyrosine Kinase Inhibitor
Dosage Forms & Strengths  Â
Capsule   Â
20mg  Â
80mg  Â
Tablet   Â
20mg  Â
40mg  Â
60mg  Â
140
mg
orally
once a day
If BSA > or equal to 1.2 m2, 60 mg given orally per day
The treatment needs to be continued until disease progression or unacceptable toxicity occurs
60
mg
orally
once a day
The treatment needs to be continued until disease progression or unacceptable toxicity occurs
when given with a combination of nivolumab
40 mg given orally once a day
The treatment needs to be continued until disease progression or unacceptable toxicity occurs
60
mg
orally
once a day
The treatment needs to be continued until disease progression or unacceptable toxicity occurs
Dosage Forms & Strengths  Â
Tablet  Â
20mg  Â
40mg  Â
60mg  Â
If BSA > or equal to 1.2 m2, 60 mg given orally per day
If BSA < or equal to 1.2 m2, 40 mg given orally per day
The treatment needs to be continued until disease progression or unacceptable toxicity occurs
cabozantinib :they may diminish the serum concentration of CYP3A4 Inducers
cabozantinib :they may diminish the serum concentration of CYP3A4 Inducers
cabozantinib :they may diminish the serum concentration of CYP3A4 Inducers
cabozantinib :they may diminish the serum concentration of CYP3A4 Inducers
cabozantinib :they may diminish the serum concentration of CYP3A4 Inducers
when both drugs are combined, there may be an increased effect of cabozantinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
when both drugs are combined, there may be a decreased effect of cabozantinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
when both drugs are combined, there may be a decreased effect of cabozantinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
when both drugs are combined, there may be an increased effect of cabozantinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
when both drugs are combined, there may be a decreased effect of cabozantinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
when both drugs are combined, there may be a decreased effect of cabozantinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
when both drugs are combined, there may be an increased effect of cabozantinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
when both drugs are combined, there may be an increased effect of cabozantinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
when both drugs are combined, there may be a decreased effect of cabozantinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
when both drugs are combined, there may be an increased effect of cabozantinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
when both drugs are combined, there may be an increased effect of cabozantinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
when both drugs are combined, there may be an increased effect of cabozantinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
It may diminish the effect when combined with phenobarbital by affecting the intestinal/hepatic enzyme CYP3A4
It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism
nafcillin will decrease the effect of action of cabozantinib by affecting enzyme CYP3A4 metabolism.
CYP3A strong enhancers of the small intestine may reduce the bioavailability of cabozantinib
when both drugs are combined, there may be an increased effect of cabozantinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
when both drugs are combined, there may be an increased effect of cabozantinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
when both drugs are combined, there may be an increased effect of cabozantinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
when both drugs are combined, there may be an increased effect of cabozantinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
when both drugs are combined, there may be an increased effect of cabozantinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
when both drugs are combined, there may be an increased effect of cabozantinib   
when both drugs are combined, there may be an increased effect of cabozantinib  
when both drugs are combined, there may be an increased effect of cabozantinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
when both drugs are combined, there may be an increased effect of cabozantinib  
when both drugs are combined, there may be an increased effect of cabozantinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
when both drugs are combined, there may be an increased effect of cabozantinib  
when both drugs are combined, there may be an increased effect of cabozantinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
It may enhance the serum concentration when combined with CYP3A4 Inhibitors (Moderate)
It may enhance the serum concentration when combined with CYP3A4 Inhibitors (Moderate)
It may enhance the serum concentration when combined with CYP3A4 Inhibitors (Moderate)
It may enhance the serum concentration when combined with CYP3A4 Inhibitors (Moderate)
It may enhance the serum concentration when combined with CYP3A4 Inhibitors (Moderate)
It may enhance the effect when combined with grapefruit by CYP3A4 metabolism
Combining cabozantinib with pranlukast may cause a reduction in the cabozantinib’s metabolism
Combining tegafur with cabozantinib can reduce tegafur’s metabolism
When domeperidone and cabozantinib is used together, this leads to reduction in the domeperidone’s metabolism
cabozantinib: they may enhance the serum concentration of CYP3A Inhibitors
cabozantinib: they may enhance the serum concentration of CYP3A Inhibitors
cabozantinib: they may enhance the serum concentration of CYP3A Inhibitors
cabozantinib: they may enhance the serum concentration of CYP3A Inhibitors
cabozantinib: they may enhance the serum concentration of CYP3A Inhibitors
When cabozantinib is used together with fluconazole, this leads to reduction in the cabozantinib metabolism
When indisulam is used together with cabozantinib, this leads to a reduction in cabozantinib metabolism
cabozantinib: it may increase the risk of methemoglobinemia with ambroxol
cabozantinib: it may increase the risk or severity of QTc prolongation agents
cabozantinib: it may increase the risk or severity of QTc prolongation agents
cabozantinib: it may increase the risk or severity of QTc prolongation agents
cabozantinib: it may increase the risk or severity of QTc prolongation agents
cabozantinib: it may increase the risk or severity of QTc prolongation agents
cabozantinib: it may decrease the metabolism of sulfamethoxazole
when both drugs are combined, there may be a decreased metabolism of paclitaxel 
the effect of cabozantinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
CYP3A4 inhibitors increase the concentration of cabozantinib in serum
It may enhance the serum concentration of cabozantinib
MRP2 inhibitors increase the concentration of cabozantinib in serum
Tipranavir may enhance the therapeutic concentration of cabozantinib
rifabutin: they may diminish the serum concentration of cabozantinib
the therapeutic efficacy of carbimazole can be decreased when used in combination with cabozantinib
Cabozantinib inhibits angiogenesis and tumor cell growth by targeting and blocking multiple receptor tyrosine kinases that are critical for tumor development, progression, and metastasis. These include kinases such as MET, VEGFR, and AXL, which are involved in cellular proliferation, migration, and survival. Clinically, cabozantinib is approved for the treatment of advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and medullary thyroid carcinoma (MTC). In addition to its approved uses, cabozantinib is also being investigated for potential effectiveness in various other solid tumors.
Adverse drug reactions:  Â
Frequency defined  Â
>10%  Â
Increased ALT  Â
increased AST  Â
increased alkaline phosphatase  Â
Hyperbilirubinemia  Â
Diarrhea  Â
Stomatitis  Â
Palmar-Plantar Erythrodysesthesia Syndrome  Â
rash  Â
dry skin  Â
alopecia  Â
erythema  Â
oral pain  Â
constipation   Â
abdominal pain  Â
vomiting  Â
dysphagia  Â
dyspepsia  Â
1-10%  Â
Hypotension  Â
Hyperkeratosis  Â
folliculitis  Â
acne  Â
blister  Â
abnormal hair growth  Â
skin exfoliation  Â
skin hypopigmentation  Â
venous thromboembolism  Â
arterial thromboembolism  Â
atrial fibrillation  Â
Hemorrhoids  Â
GI perforation  Â
GI fistula  Â
GI hemorrhage  Â
pancreatitis  Â
fissure  Â
anal inflammation  Â
cheilitis  Â
0.1-1%  Â
Angina pectoris  Â
Esophagitis  Â
supraventricular tachycardia  Â
Amenorrhea  Â
shortened activated partial thromboplastin time  Â
Frequency not defined   Â
QT interval prolongation  Â
Hemorrhage
None
Cabozantinib is contraindicated in individuals with a known hypersensitivity to the drug or any of its components. Several precautions should be taken when administering cabozantinib due to the risk of serious adverse events. There is a potential for fatal hemorrhage, particularly in patients with squamous cell histology, necessitating close monitoring. Gastrointestinal perforations and fistulas have also been reported and may be life-threatening. Hypertension is a common side effect and should be actively monitored and managed during treatment. Because cabozantinib can impair wound healing, it should be discontinued prior to surgical procedures. Thromboembolic events, including both arterial and venous thromboses, have occurred in some patients. Additionally, the drug may prolong the QT interval, so caution is advised in patients with predisposing factors. In those with hepatic impairment, dose adjustments may be necessary to avoid toxicity.Â
Pregnancy warnings:   Â
Breastfeeding warnings:Â
Pregnancy Categories:     Â
Absorption:Â
Cabozantinib is well absorbed after oral administration, although its absolute bioavailability has not been fully established.Â
Distribution:Â
Once absorbed, cabozantinib distributes extensively throughout the body, with a volume of distribution of approximately 319 liters. It is highly bound to plasma proteins, with more than 99.7% bound primarily to albumin, indicating limited free drug available in circulation.Â
Metabolism:Â
Metabolism of cabozantinib occurs predominantly in the liver, primarily via the cytochrome P450 enzyme CYP3A4. Minor contributions from CYP1A1 and UGT1A1 are also noted. The drug is metabolized into several active and inactive metabolites, some of which retain pharmacologic activity.Â
Excretion:Â
Excretion of cabozantinib is slow, consistent with its long terminal half-life of approximately 99 hours. It is eliminated primarily through the feces (about 54%) and to a lesser extent via the urine (approximately 27%). The drug’s prolonged half-life and high protein binding contribute to its sustained presence in the body and necessitate careful dosing and monitoring.Â
Cabozantinib is available in two oral dosage forms: tablets marketed under the brand name Cabometyx and capsules marketed as Cometriq. These formulations are approved for different indications and are not interchangeable. When administering cabozantinib, it should be taken on an empty stomach—specifically, at least two hours after eating and one hour before consuming any food. The tablets or capsules must be swallowed whole with water and should not be crushed, chewed, or opened to ensure proper drug delivery and efficacy.Â
Pronunciation:Â ka-boe-ZAN-ti-nibÂ
Cabozantinib is a drug from the anti-cancer class. It treats a variety of cancers, including kidney, liver, and thyroid.
It belongs to a class of tyrosine kinase inhibitors that works by retarding or ceasing the cancerous cell growth.
The patient information leaflet contains the advice required by the patients for the dose regimen. It is available with the pharmacist.
Take the medication once daily through the mouth. Don’t take this medicine with meals and only on an empty stomach. Take it before 2 hours or after 1 hour of taking the meal.
Take plenty of water with it. Avoid the consumption of grapefruit or its juice as it increases side effects when taken with medicine.
Do not tamper with or break the solid dose of medicine.
The dose is related to your previous medical condition; discuss it with your physician if you suffer from any disease.
Side effects during the treatment may include nausea, dizziness, diarrhea, mouth ulcers, vomiting, stomach pain, constipation, weakness, tiredness, and weight loss. If the effects get worsen, immediately consult your doctor.
Cabozantinib rarely causes any side effects that may be fatal or serious, like a peptic ulcer or bleeding.
It would be best to always inform your doctor about any minor or significant discomfort after taking the medication. If you have any previous allergies, tell them also to your doctor.
Avoid encountering the people having the infection.
To check on a missed dose, you must take the amount as soon as you remember and should not double the dose if the skipped dose is near to the next dose.
Store the medication at room temperature and away from sunlight/moisture. Keep the product away from pets and children.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
